

# Kevin R Bewley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6739770/publications.pdf>

Version: 2024-02-01

39  
papers

12,907  
citations

257450

24  
h-index

276875

41  
g-index

48  
all docs

48  
docs citations

48  
times ranked

20776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	13.7	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	13.7	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	13.7	1,196
4	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	13.7	979
5	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	28.9	936
6	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	30.7	900
7	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
8	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	28.9	442
9	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	11.0	298
10	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
11	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021, 16, 3114-3140.	12.0	195
12	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. <i>Nature Communications</i> , 2021, 12, 81.	12.8	141
13	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021, 12, 1260.	12.8	115
14	Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. <i>Journal of General Virology</i> , 2015, 96, 3484-3492.	2.9	113
15	Assessment of the Protective Effect of Imvamune and Acam2000 Vaccines against Aerosolized Monkeypox Virus in Cynomolgus Macaques. <i>Journal of Virology</i> , 2013, 87, 7805-7815.	3.4	106
16	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. <i>EBioMedicine</i> , 2021, 63, 103153.	6.1	76
17	Real-time PCR system targeting a chromosomal marker specific for <i>Bacillus anthracis</i> . <i>Molecular and Cellular Probes</i> , 2008, 22, 313-315.	2.1	74
18	Dengue Virus Serotype 3, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007, 13, 182-183.	4.3	62

#	ARTICLE	IF	CITATIONS
19	Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection. <i>Viruses</i> , 2021, 13, 113.	3.3	56
20	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020, 12, 1164.	3.3	51
21	Nosocomial Buffalopoxvirus Infection, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007, 13, 902-904.	4.3	42
22	Antiviral Screening of Multiple Compounds against Ebola Virus. <i>Viruses</i> , 2016, 8, 277.	3.3	37
23	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021, 10, .	6.0	28
24	Animal models of Q fever ( <i>Coxiella burnetii</i> ). <i>Comparative Medicine</i> , 2013, 63, 469-76.	1.0	27
25	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , 2021, 6, 83.	6.0	25
26	Efficacy of Liposome-Encapsulated Ciprofloxacin in a Murine Model of Q Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5510-5518.	3.2	24
27	Sequence of Pathogenic Events in Cynomolgus Macaques Infected with Aerosolized Monkeypox Virus. <i>Journal of Virology</i> , 2015, 89, 4335-4344.	3.4	24
28	In vitro susceptibility of <i>Coxiella burnetii</i> to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. <i>International Journal of Antimicrobial Agents</i> , 2004, 24, 194-195.	2.5	20
29	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	10.3	20
30	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. <i>Scientific Reports</i> , 2020, 10, 21894.	3.3	18
31	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	4.4	15
32	Poliovirus type 1 in working stocks of typed human rhinoviruses. <i>Lancet, The</i> , 2003, 361, 1187-1188.	13.7	14
33	Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques. <i>Frontiers in Immunology</i> , 2021, 12, 801799.	4.8	14
34	Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using <i>In Vitro</i> and <i>In Vivo</i> Models of Q Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0067321.	3.2	7
35	Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye. <i>Journal of Virology</i> , 2021, 95, e0083321.	3.4	6
36	A black necrotic ulcer. <i>Lancet, The</i> , 2003, 361, 1518.	13.7	5

#	ARTICLE	IF	CITATIONS
37	Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever. <i>Frontiers in Microbiology</i> , 2021, 12, 760698.	3.5	5
38	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
39	Development of a quantitative real-time RT-PCR assay that differentiates between Kyasanur Forest disease virus and Alkhurma hemorrhagic fever virus. <i>Ticks and Tick-borne Diseases</i> , 2020, 11, 101381.	2.7	1